Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: We conducted a phase I crossover study of escalating doses of both paclitaxel (Taxol; Bristol-Myers, Squibb, Princeton, NJ) and r-verapamil, the less cardiotoxic stereoisomer, in heavily pretreated patients with metastatic breast cancer. PATIENTS AND METHODS: Twenty-nine patients refractory to paclitaxel by 3-hour infusion were treated orally with r-verapamil every 4 hours starting 24 hours before the same-dose 3-hour paclitaxel infusion and continuing for a total of 12 doses. Once the maximum-tolerated dose (MTD) of the combination was determined, seven additional patients who had not been treated with either drug were evaluated to determine whether the addition of r-verapamil altered the pharmacokinetics of paclitaxel. Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression before receiving paclitaxel and after becoming refractory to paclitaxel therapy. RESULTS: The MTD of the combination was 225 mg/m2 of r-verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion. Dose-limiting hypotension and bradycardia were observed in three of five patients treated at 250 mg/m2 r-verapamil. Fourteen patients received 32 cycles of r-verapamil at the MTD as outpatient therapy without developing cardiac toxicity. The median peak and trough serum verapamil concentrations at the MTD were 5.1 micromol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR). Increased serum verapamil concentrations and cardiac toxicity were observed more frequently in patients with elevated hepatic transaminases and bilirubin levels. Hematologic toxicity from combined paclitaxel and r-verapamil was significantly worse compared with the previous cycle of paclitxel without r-verapamil. In the pharmacokinetic analysis, r-verapamil delayed mean paclitaxel clearance and increased mean peak paclitaxel concentrations. CONCLUSION: r-Verapamil at 225 mg/m2 orally every 4 hours can be given safely with paclitaxel 200 mg/m2 by 3-hour infusion as outpatient therapy and is associated with serum levels considered active for Pgp inhibition. The addition of r-verapamil significantly alters the toxicity and pharmacokinetics of paclitaxel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Cited by
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
Varma, M. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00158-0 · Cited by 418
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Metadata
- Authors
- Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., Noone, M. H., Denicoff, A. M., Barnes, C. S., Gossard, M. R., Fetsch, P. A., Berg, S. L., Balis, F. M., Venzon, D. J., & O'Shaughnessy, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-04
- Volume
- 14
- Issue
- 4
- Pages
- 1173-1184
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156213555
- Cited by
- 73
- References
- 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.1996.14.4.1173
- The paper
- Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., Noone, M. H., Denicoff, A. M., Barnes, C. S., Gossard, M. R., Fetsch, P. A., Berg, S. L., Balis, F. M., Venzon, D. J., & O'Shaughnessy, J. A. (1996). Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.4.1173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.